IRIDEX (IRIX) Akcija Цена

IRIDEX Цена

NASDAQ·ZATVORENO
0,44
​
Tržište je zatvoreno

U poslednjih 19 godina prihod IRIDEX rastao je 2,0 % godišnje i dostigao 52,68 М USD. Zarada po akciji padala je 26,3 % godišnje u poslednjih 6 godina. Za IRIDEX neto marža od -8,4 % je porasla u odnosu na -9,7 % pre nekoliko godina.

Cena akcije IRIDEX

Pristupite ovim podacima preko Eulerpool API-ja

100.000 zahteva/mes. besplatno · bez kartice

IRIDEX poslovni model i analiza akcije

IRIDEX Corp je globalna kompanija za medicinsku tehnologiju koja se specijalizovala za razvoj, proizvodnju, marketing i distribuciju inovativnih laserskih medicinskih uređaja i usluga. Kompanija je osnovana 1989. godine, a sedište joj se nalazi u Mountain Viewu u Kaliforniji. Poslovni model IRIDEX-a podeljen je na različite odeljenja, od kojih svako služi različitim tržištima. Odeljenja uključuju oftalmologiju, otorinolaringologiju (ENT), ginekologiju i urologiju, kao i naučna istraživanja. Kompanija nudi širok spektar visokotehnoloških laserskih sistema koji se mogu koristiti za lečenje različitih stanja, poput retinalnih bolesti, glaukoma, poremećaja nosa i grla, ginekoloških i uroloških oboljenja, kao i drugih medicinskih primena. Jedno od najpoznatijih odeljenja IRIDEX-a je oftalmologija, koja nudi širok spektar laserskih sistema za lečenje retinalnih bolesti. Te retinalne bolesti uključuju dijabetičku retinopatiju, edem mrežnjače, degeneraciju makule vezanu za uzrast i odvajanje mrežnjače. Kompanija takođe poseduje visokotehnološki sistem pod nazivom Cyclo G6TM, koji se koristi za lečenje glaukoma. Ovaj sistem može se koristiti i u kombinaciji sa drugim uređajima, poput ultrazvučnih sistema, radi optimizacije kliničke efikasnosti. Odeljenje ENT nudi laserske sisteme za lečenje poremećaja nosa i grla, poput hrkanja, polipa, stenoze i tumora. Asortiman laserskih sistema varira od jednostavnih do naprednih sistema koji se mogu povezati sa fleksibilnim endoskopom radi preciznijeg lečenja. Odeljenje za ginekologiju i urologiju IRIDEX-a nudi laserske sisteme za različite primene, poput urinarnog inkontinencije, problema sa mokraćnom bešikom, uklanjanja tumora, uklanjanja tkiva prostate i medicinskih tretmana za poboljšanje seksualne funkcije. Laserski sistemi se takođe mogu koristiti u kombinaciji sa drugim medicinskim uređajima, poput ultrazvučnih sistema. Kompanija pridaje veliki značaj naučnim istraživanjima i razvoju kako bi kreirala i predstavila inovativne tehnologije na tržište. Stoga, IRIDEX usko sarađuje sa različitim istraživačkim institutima, univerzitetima i medicinskim stručnjacima kako bi dalje razvijala svoja tehnološka dostignuća. Kompanija je takođe posvećena pružanju sveobuhvatnog obučavanja i podrške svojim kupcima kako bi se osiguralo da uređaje koriste bezbedno i efikasno. U celini, IRIDEX Corp je utvrdio svoj položaj kao inovativna i moćna multinacionalna kompanija u oblasti medicinske tehnologije. Kompanija stalno teži proširenju svog asortimana proizvoda i usluga i impresionira svoje kupce visokokvalitetnim rešenjima. IRIDEX je siguran da će i ubuduće imati značajnu ulogu u industriji medicinske tehnologije.

Često postavljana pitanja o akciji IRIDEX

The business model of IRIDEX Corp focuses on developing, manufacturing, and marketing medical laser systems and delivery devices for the treatment of eye diseases and conditions. With a comprehensive portfolio of products, the company aims to provide innovative solutions to both ophthalmologists and patients. By leveraging its cutting-edge laser technology, IRIDEX Corp aims to improve the standards of care and enhance patient outcomes in the field of ophthalmology.

IRIDEX Corp is primarily active in the medical technology industry.

The main competitors of IRIDEX Corp in the market are Alcon Inc., Ellex Medical Lasers Ltd., and Lumenis Ltd.

IRIDEX Corp is a renowned medical technology company specializing in the development and commercialization of innovative laser systems for the treatment of various eye diseases. Founded in 1989, IRIDEX has since garnered a strong reputation for its cutting-edge products and advanced therapeutic solutions. The company boasts a rich history, marked by significant milestones and achievements in the field of ophthalmology. Guided by a commitment to revolutionize the way eye diseases are diagnosed and treated, IRIDEX remains at the forefront of the industry, continually striving to enhance patient outcomes through its state-of-the-art technologies.

IRIDEX Corp has achieved numerous significant milestones over the years. The company has successfully emerged as a leading provider of laser-based medical solutions, specializing in treating sight-threatening eye conditions. Notably, IRIDEX Corp introduced the innovative MicroPulse technology, which revolutionized the way retinal diseases are treated. Additionally, the company has expanded its product portfolio and global presence. IRIDEX Corp's dedication to technological advancements and commitment to enhancing patient outcomes have contributed to its position as a trusted name in ophthalmic healthcare.

IRIDEX Corp is primarily present in the United States.

IRIDEX Corp represents values of innovation, excellence, and patient-centricity. With a corporate philosophy centered around advancing patient care, IRIDEX Corp is committed to delivering cutting-edge medical solutions for eye diseases. The company strives to improve outcomes and enhance the quality of life for patients through the development and commercialization of minimally invasive laser-based medical devices. By combining state-of-the-art technology and a patient-first approach, IRIDEX Corp aims to revolutionize the treatment of retinal diseases and glaucoma. Through its commitment to innovation and dedication to improving patient outcomes, IRIDEX Corp has established itself as a leading player in the ophthalmic medical device industry.

7 analitičara trenutno ocenjuje akciju IRIDEX: 6 preporučuje kupovinu, 1 držanje i 0 prodaju. Za 2026 analitičari očekuju da IRIDEX ostvari prihod 52,52 М USD i zaradu po akciji -0,12 USD.

Po trenutnom kursu akcija IRIDEX kotira 0,41 EUR (0,44 USD).

Akcija IRIDEX (IRIX) kotira na 1 berze, uključujući: NASDAQ (IRIX).

IRIDEX Corporation is a leading company specializing in the development, manufacture, and sale of medical laser systems and accessories. The company offers a wide range of products and services targeting various customers including doctors, ophthalmologists, medical device providers, and surgical centers worldwide. The company specializes in two main divisions: ophthalmology and aesthetic dermatology. In the ophthalmology division, IRIDEX offers a variety of laser systems and system accessories focusing on the treatment of retinal diseases and glaucoma, as well as cosmetic and therapeutic procedures. The company is particularly known for its proven laser system, the "PASCAL Photocoagulator," which is considered one of the most advanced retinal laser therapy systems. IRIDEX's ophthalmology division also offers other innovative products such as the IRIS Medical SoftFit Gonioscope for glaucoma diagnosis. IRIDEX is also active in aesthetic dermatology, offering products for hair removal, wrinkle treatment, vascular treatment, and the treatment of common skin issues like acne. The flagship products in this area are the "GentleMAXPro" laser system and the multifunctional aesthetic system "Apogee+." The company generates revenue through the sale of devices and accessories, including consumables, as well as services such as training and support. IRIDEX sells its products in over 100 countries, targeting markets in Europe, North America, and Asia. It serves its customers directly through its subsidiaries or through distribution partners. The company's business model is based on a combination of research and development, marketing and sales, customer care, and efficiency assurance in production. IRIDEX engineers constantly work to improve the effectiveness and usability of their products, creating patient-oriented solutions based on scientifically proven results. IRIDEX has also entered into distribution agreements with global distributors to market and sell its products worldwide. IRIDEX aims to improve the standards and procedures of laser technology and continuously optimize patient care in the fields of ophthalmology and aesthetic dermatology. The company strives to build long-term relationships with clinicians and scientists to deliver advanced solutions in the medical device industry. In summary, IRIDEX is a company dedicated to advanced laser technology and accessories for ophthalmology and aesthetic dermatology. Through continuous innovation and collaborative partnerships, the company aims to support its customers with patient-oriented solutions. IRIDEX has already achieved significant milestones in its goal of establishing itself as the leading product line for global ophthalmology and aesthetic dermatology. IRIDEX Corporation is a leading company specialized in the development, manufacturing, and sale of medical laser systems and accessories. The company offers a wide range of products and services targeting various customers, including doctors, ophthalmologists, medical device providers, and surgical centers worldwide. The company is specialized in two main divisions: Ophthalmology and aesthetic dermatology. In the ophthalmology division, IRIDEX offers a variety of laser systems and system accessories focusing on the treatment of retinal diseases and glaucoma, as well as cosmetic and therapeutic procedures. The company is particularly known for its proven laser system, the "Pascal Photocoagulator," which is considered one of the most advanced retinal laser therapy systems. The IRIDEX ophthalmology division also offers other innovative products, such as the IRIS Medical SoftFit Gonioscope for glaucoma diagnosis. IRIDEX is also active in aesthetic dermatology, where it offers products for hair removal, wrinkle treatment, vascular treatment, and the treatment of common skin problems such as acne. The flagship products in this area are the "GentleMAXPro" laser system and the multifunctional aesthetic system "Apogee+." The company generates revenue through the sale of devices and accessory products, including consumables, and services such as training and support. IRIDEX sells its products in more than 100 countries, targeting markets in Europe, North America, and Asia. It serves its customers directly through its subsidiaries or through distribution partners. The company's business model is based on a combination of research and development, marketing and sales, customer support, and efficiency assurance in production. IRIDEX engineers constantly work to improve the effectiveness and usability of their products, creating patient-oriented solutions based on scientifically proven results. IRIDEX has also entered into distribution agreements with global distributors to market and sell its products worldwide. IRIDEX aims to improve the standards and procedures of laser technology and continuously optimize patient care in the fields of ophthalmology and aesthetic dermatology. The company strives to build long-term relationships with clinicians and scientists to deliver advanced solutions in the medical device industry. In summary, IRIDEX is a company dedicated to advanced laser technology and accessory products for ophthalmology and aesthetic dermatology. Through continuous innovation and collaborative partnerships, the company aims to support its customers with patient-oriented solutions. IRIDEX has already achieved significant milestones in its goal of establishing itself as a leading product line for global ophthalmology and aesthetic dermatology.

očekivana prihod od IRIDEX je 52,52 М USD. Ova cifra je zasnovana na trenutnim finansijskim podacima i odražava poslovne rezultate preduzeća.

očekivana dobit od IRIDEX je -2,06 М USD. Neto dobit pokazuje profitabilnost preduzeća nakon odbitka svih troškova.

Odnos cene i zarade (KGV) za IRIDEX je trenutno -3,71. KGV poredi sadašnju cenu akcije sa zaradom po akciji i pomaže investitorima da procene valuaciju akcije IRIDEX.

Odnos cene i prihoda (KUV) za IRIDEX je trenutno 0,15. KUV poredi tržišnu kapitalizaciju sa godišnjim prihodima i služi kao metrika valuacije za akciju IRIDEX.

Eulpool score kvaliteta za IRIDEX je 1/10.

ISIN za IRIDEX je US4626841013. ISIN (International Securities Identification Number) je globalno jedinstveni identifikator za hartije od vrednosti.

WKN za IRIDEX je 912341. WKN (Wertpapierkennnummer) je šestocifreni nemački broj za identifikaciju hartija od vrednosti.

Ticker za IRIDEX je IRIX. Simbol tikera se koristi za trgovinu akcijama IRIDEX na berzanskom tržištu.

Фер вредностTerminal
0,37 USD
Над-/ПодцењеностTerminal
Адекватно вредна
Сектор
Индустрија
Медицинска опрема и понуде
Број акција
Запослени
Приход по запосленом
566.397,85 USD
Раст прихода Ø5 година
Раст EBIT Ø5 година
Раст нето добити Ø5 година
Веб сајт iridex.com
Валута
USD
Јавна понуда
16. феб 1996.
ISIN
US4626841013
CUSIP
462684101
SEDOL
2476375
Тржишна капитализација
7,65 М USDMicro Cap
Опсег од 52 недеље
AAQS
1 / 10
PEG
—
P/E однос
P/Ee 2026
-3,71
P/Ee 2027
—
P/Ee 2028
6,36
P/S
P/Se
0,15
EV/EBIT
—
P/B однос
1,55
ROE (Поврат на капитал)
ROA (Поврат на имовину)
ROCE (Поврат на ангажовани капитал)
ROIC (Поврат на уложени капитал)
-46,93 %
Zadnje ažurirano 21. нов 2026. 11:07

IRIDEX Тикер

NASDAQ · IRIX

IRIDEX FIGI

IRIX:US · BBG000BZB346IRIX:UA · BBG000BZB3G3IRIX:UC · BBG000BZB3W5IRIX:UN · BBG000BZB4G1IRIX:UP · BBG000BZB4T7IRIX:UQ · BBG000BZB578IRIX:UB · BBG000BZB5C2IRIX:UM · BBG000BZB5Y8IRIX:UX · BBG000BZB658IRIX:UD · BBG000BZB9Q9IRIX:UF · BBG000BZBCG3IRIX:VY · BBG000BZBCR1

Sve ključne metrke i detaljne analize IRIDEX u dubinskoj analizi

Naša analiza akcija za akciju IRIDEX uključuje važne finansijske pokazatelje kao što su prihod, profit, P/E odnos, P/S odnos, EBIT, kao i informacije o dividendama. Takođe, razmatramo aspekte poput akcija, tržišne kapitalizacije, dugova, kapitala i obaveza kompanije IRIDEX. Ako tražite detaljnije informacije o ovim temama, na našim podstranicama vam nudimo opsežne analize: